股本结构
单位：万股
| 公告日期 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-06-30 | 2023-05-15 | 2023-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 3795.80 | 3795.37 | 3794.94 | 3794.51 | 2693.37 | 2646.50 |
| 普通股本 | 3795.80 | 3795.37 | 3794.94 | 3794.51 | 2693.37 | 2646.50 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-06-28 | 2023-05-12 | 2023-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-19 | 3795.80 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common shares, net of offering costs of $1.4 million
Issuance of common shares in settlement of deferred stock units
Issuance of common shares in settlement of restricted stock units
|
2023-12-31 |
| 2023-11-13 | 3795.37 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common shares upon the vesting of restricted stock units
|
2023-09-30 |
| 2023-08-14 | 3794.94 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common shares net of offering costs of $1.4 million
Issuance of common shares upon the vesting of restricted stock units
|
2023-06-30 |
| 2023-06-30 | 3794.51 | 未披露 | 定期报告 | 2023-06-28 |
| 2023-05-15 | 2693.37 | 未披露 | 定期报告 | 2023-05-12 |
| 2023-05-15 | 2646.50 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common shares in settlement of deferred stock units
Issuance of common shares upon the vesting of restricted stock units
|
2023-03-31 |
| 2023-03-28 | 2646.07 | 未披露 | 定期报告 | 2023-03-28 |
| 2022-03-14 | 2644.31 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common shares, net of offering costs of $151
Exercise of common stock options
Issuance of common shares in settlement of deferred stock units
|
2021-12-31 |
| 2021-11-10 | 2643.92 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common shares net of offering costs of $0.1 million
Share-based compensation expense
|
2021-09-30 |
| 2021-05-05 | 1878.62 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Exercise of common stock options
|
2021-03-31 |
| 2021-03-10 | 1877.62 | 未披露 | 定期报告 | 2021-03-05 |
| 2021-03-10 | 1874.62 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common shares, net of offering costs of $2,694
Exercise of common stock options
|
2020-12-31 |
| 2020-11-04 | 1873.91 | 未披露 |
更多>>
1.Common shares offered by the company 4,000,000 shares.
2.The number of common shares to be outstanding after this offering is based on 14,139,074 common shares outstanding as of March 31, 2020.
From June 30, 2020 to September 30, 2020
Issuance of common shares net of offering costs of $1.8 million
|
2020-08-10 |
| 2020-05-13 | 1413.91 | 未披露 |
更多>>
From December 31, 2019 to March 20, 2020
Issuance of common shares net of offering costs of $819
Exercise of common stock options
|
2020-03-20 |
| 2020-02-13 | 1413.19 | 未披露 |
更多>>
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The offering is expected to close on or about February 13, 2020, subject to the satisfaction of customary closing conditions.
|
2020-02-13 |
| 2019-08-13 | 1200.69 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Exercise of common stock option
Share-based compensation
|
2019-06-30 |
| 2019-03-19 | 1195.69 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common shares and warrants, net of offering costs of $529
Issuance of common shares, net of offering costs of $1,674
Exercise of common share purchase warrants
Exercise of common stock option
|
2018-12-31 |
| 2018-12-10 | 1193.92 | 未披露 |
更多>>
1.Common shares offered 4,100,000 shares
|
2018-12-07 |
| 2018-11-27 | 785.69 | 未披露 | 定期报告 | 2018-11-23 |
| 2018-11-19 | 783.92 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-11-09 | 15666.38 | 未披露 | 定期报告 | 2018-06-30 |
From December 31,2022 to December 31,2023
Issuance of common shares, net of offering costs of $1.4 million
Issuance of common shares in settlement of deferred stock units
Issuance of common shares in settlement of restricted stock units
From June 30, 2023 to September 30, 2023
Issuance of common shares upon the vesting of restricted stock units
From March 31, 2023 to June 30, 2023
Issuance of common shares net of offering costs of $1.4 million
Issuance of common shares upon the vesting of restricted stock units
From December 31, 2022 to March 31, 2023
Issuance of common shares in settlement of deferred stock units
Issuance of common shares upon the vesting of restricted stock units
From December 31, 2020 to December 31, 2021
Issuance of common shares, net of offering costs of $151
Exercise of common stock options
Issuance of common shares in settlement of deferred stock units
From June 30, 2021 to September 30, 2021
Issuance of common shares net of offering costs of $0.1 million
Share-based compensation expense
From December 31, 2020 to March 31, 2021
Exercise of common stock options
From December 31, 2019 to December 31, 2020
Issuance of common shares, net of offering costs of $2,694
Exercise of common stock options
1.Common shares offered by the company 4,000,000 shares.
2.The number of common shares to be outstanding after this offering is based on 14,139,074 common shares outstanding as of March 31, 2020.
From June 30, 2020 to September 30, 2020
Issuance of common shares net of offering costs of $1.8 million
From December 31, 2019 to March 20, 2020
Issuance of common shares net of offering costs of $819
Exercise of common stock options
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica. The offering is expected to close on or about February 13, 2020, subject to the satisfaction of customary closing conditions.
From March 31, 2019 to June 30, 2019
Exercise of common stock option
Share-based compensation
from December 31, 2017 to December 31, 2018
Issuance of common shares and warrants, net of offering costs of $529
Issuance of common shares, net of offering costs of $1,674
Exercise of common share purchase warrants
Exercise of common stock option
1.Common shares offered 4,100,000 shares